Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

ns. In these roles, he managed clinical development activities for a variety of therapeutic areas, including oncology, infectious diseases, women's health, sleep and central nervous system. Prior to Searle/Pharmacia, Dr. Sherman was at Squibb/Bristol-Myers Squibb in Clinical Pharmacology and Clinical Research.

Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed both an internship and residency in internal medicine at the Northwestern University McGaw Medical Center, where he also served as a chief medical resident. In addition, Dr. Sherman completed fellowship training at the University of California, San Francisco (UCSF) and also served as a research associate at the Howard Hughes Medical Institute at UCSF. Dr. Sherman is currently a Board Member of the Drug Information Association (DIA) and will be chairing the DIA 2008 Annual Meeting.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE and to respond to other matters raised by ODAC and the FDA, the Company's confidence that the proposed NDA amendment will provide substantial evidence for the continued regulatory approval process, the
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Md. , April 1, 2015  VLP Therapeutics, ... company focusing on the research and development of therapeutic ... upon a novel and proprietary vaccine technology, today announced ... Institute of Tropical Medicine at Nagasaki ... collaboration will facilitate VLP,s research and development of dengue ...
(Date:4/1/2015)... April 1, 2015  EMD Serono, the U.S. biopharmaceuticals ... , announced today the appointment of Frederick E. ... and Immunology. In this capacity, he will lead the ... projects and collaborations for Rebif ® (interferon beta-1a) ... Dr. Munschauer joins EMD Serono from ...
(Date:4/1/2015)... Canada,s Research-Based Pharmaceutical Companies (Rx&D) acknowledges the ... Cost Drivers of Public Drug Plans in Canada ... rates of change in drug costs have been steadily declining ... 2012/13 for a number of select public drug plans. But ... medicines without considering their overall impact on the system and ...
(Date:4/1/2015)... , April 1, 2015 Synthetic Biologics, ... therapies for serious infections and diseases, with a ... clinical data supporting the development of SYN-004, the ... intravenous (IV) antibiotics within the gastrointestinal (GI) tract ... microbiome for the prevention of C. difficile ...
Breaking Biology Technology:VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4
... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... banking operator in China, today announced the completion of ... holders to receive one ordinary share for every eight ... to 2.2% of shares outstanding as of December 10, ...
... Research Group, Inc. finds that with the introduction of Novartis, ... of multiple sclerosis (MS), neurologists anticipate major shifts in the ... of Gilenya, trial and uptake of Extavia, a DMA launched ... to the perception that Extavia is a "me too" agent ...
... 2010 Scientists from Pacific Biosciences of California, Inc. ... single molecule, real-time (SMRT) DNA sequencing technology to rapidly ... epidemic in Haiti. Published Thursday in the ... the first whole genome sequence analysis and most detailed ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of Warrant Exchange 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 2Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 3
(Date:4/1/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces the second shipment of ... to early access pre-order customers. Feedback ... outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop & ... at all outlets and very easy to use. Several ...
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... declining worldwide, and their declines far exceed those of ... are listed as threatened according to the Red List ... (IUCN). Multiple factors threaten global amphibian diversity but the ... poorly known. A new study published in Nature ...
... Physical activity will definitely lower children,s chances of developing ... not necessarily increase it. Findings from a recent Queen,s ... have different consequences for young people,s health. "Even ... really only making up a short period of their ...
... we regret, buy things we really don,t need, engage in ... are different kinds of hastiness and rashness embedded in our ... yes -- especially if you,re a man. The ... Scott Stoltenberg, found links between impulsivity and a rarely researched ...
Cached Biology News:Predicting future threats for global amphibian biodiversity 2Study IDs new genetic links to impulsivity, alcohol problems in men 2
... in-house demand is causing shortages in your laboratory ... can cause unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your idea ... it internationally. We work under ISO 9001 quality ...
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, ... Receive royalties for your hard work ... let us build it up,and market it ...
... virus is a type I eukaryotic topoisomerase ... turns (also called right- and left-handed supercoils) ... the reaction is a covalently closed, circular ... turns. DNA Topoisomerase I does not absolutely ...
...
Biology Products: